<MedlineCitation Status="Completed">
<MedlineID>10011933</MedlineID>
<PMID>421173</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2001</Year>
<Month>03</Month>
<Day>23</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0008-543X</ISSN>
<JournalIssue>
<Volume>43</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Cervix cancer: treatment with combination vincristine and high doses of methotrexate.</ArticleTitle>
<Pagination>
<MedlinePgn>459-64</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Patients with carcinoma of the cervix (31) and of the vulva (2) were treated with high doses of Methotrexate. The objective response rate was 17% with a median duration of 3 months. Three toxic deaths occurred. The response rate of high dose methotrexate in advanced and prior treated cervix cancer does not differ from that reported in prior studies with conventional doses of intravenous methotrexate.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Hakes</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Nikrui</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Magill</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author>
<LastName>Ochoa</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Suffix>Jr</Suffix>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>57-22-7</RegistryNumber>
<NameOfSubstance>Vincristine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>59-05-2</RegistryNumber>
<NameOfSubstance>Methotrexate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cervix Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Methotrexate</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &#38; dosage</QualifierName>
<QualifierName>adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Middle Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Remission, Spontaneous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Stomatitis</DescriptorName>
<QualifierName>chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Vincristine</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Vulvar Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
